Press releases
Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.
2026
26 Mar 2026, 07:00 | Regulatory
20 Mar 2026, 08:00 | Regulatory
Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Fi…
13 Mar 2026, 12:10
10 Mar 2026, 10:15
9 Mar 2026, 09:55
4 Mar 2026, 22:08 | Regulatory
· If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation.